OncoLink Cancer Treatment and Resources

Hormonal Therapy

 

Estrogen Receptor

Tamoxifen for weakly positive Estrogen and Progesterone breast cancers
Dear OncoLink "Ask The Experts," I am a 31-year old ER negative and "weakly" PR positive breast cancer patient. I have had a mastectomy with no lymph node involvement and chemotherapy and now deciding whether to go on Tamoxifen. Does your practice recommend Tamoxifen for "weakly" PR positive patients?Julia Draznin Maltzman, MD,
Estrogen plus progestin (E+P) and breast cancer incidence and mortality
Presenter: Rowan T. Chlebowski Presenter's Affiliation: Women's Health Initiative, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA Background The Women's Health Initiative (WHI) was a major research program launched in 1991 to address the most common causes of death, disability and poor quality of
Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT 0101)
Presenter: N. E. DavidsonPresenter's Affiliation: Eastern Cooperative Oncology GroupType of Session: ScientificBackground The benefits of combined chemotherapy and endocrine therapy in premenopausal pts with node-positive, hormone receptor-positive breast cancer are a topic of much research. The benefit of chemotherapy in node-positive breast
BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for post-menopausal women with receptor-positive breast cancer.
Presenter: B.J. ThurlimannPresenter's Affiliation: BIG 1-98 Collaborative, Bern, SwitzerlandType of Session: ScientificBackground Letrozole is a drug in a class of medications known as aromatase inhibitors, which almost completely inhibit the synthesis of estrogen. Tamoxifen is an estrogen receptor blocker.
A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Presenter: M. CristofanilliPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground It is well known that hormonal receptor status is an important prognostic factor in metastatic breast cancer patients and has clinical implications for hormonal therapies. 55% of metastatic breast cancer patients are
Estrogen receptor negative breast cancers
Dear OncoLink "Ask The Experts," Does breast cancer run along some continuum from estrogen-receptor positive to estrogen-receptor negative tumors? Are ER+ tumors a different disease than ER- tumors? I have been diagnosed with an ER- breast cancer and I am confused as to whether I am at increased risk of recurrence and general guidelines for
OncoLink I wish u knew...

Dr. Vapiwala discusses the public awareness of prostate cancer and the public support for the disease. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS